Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Wakelee, H."" wg kryterium: Autor


Wyświetlanie 1-13 z 13
Tytuł :
Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.
Autorzy :
Jeong Y; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.; Department of New Biology, DGIST, Daegu, Republic of Korea.
Hellyer JA; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Stehr H; Department of Pathology, Stanford University School of Medicine, Stanford, California.
Hoang NT; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.; Department of Biology, San Francisco State University, San Francisco, California.
Niu X; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Das M; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Medicine, VA Palo Alto Health Care System, Palo Alto, California.
Padda SK; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Ramchandran K; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Neal JW; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Wakelee H; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California. .
Diehn M; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California. .; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Jan 01; Vol. 26 (1), pp. 274-281. Date of Electronic Publication: 2019 Sep 23.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Mutation*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*pathology
Drug Resistance, Neoplasm/*genetics
Kelch-Like ECH-Associated Protein 1/*genetics
Lung Neoplasms/*pathology
NF-E2-Related Factor 2/*genetics
Aged ; Animals ; Carboplatin/administration & dosage ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Cisplatin/administration & dosage ; Etoposide/administration & dosage ; Female ; Humans ; Kelch-Like ECH-Associated Protein 1/metabolism ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; NF-E2-Related Factor 2/metabolism ; Neoplasm Staging ; Paclitaxel/administration & dosage ; Prognosis ; Spheroids, Cellular ; Survival Rate
Czasopismo naukowe
Tytuł :
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Autorzy :
Mazieres J; Thoracic Oncology Department, Toulouse University Hospital, Université Paul Sabatier, Toulouse, France. Electronic address: .
Drilon A; Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA.
Lusque A; Biostatistics Unit, Institut Claudius Regaud, IUCT-O, Toulouse.
Mhanna L; Thoracic Oncology Department, Toulouse University Hospital, Université Paul Sabatier, Toulouse, France.
Cortot AB; Thoracic Oncology Department, Lille University Hospital, Lille University, Lille.
Mezquita L; Cancer Medicine Department, Gustave Roussy, Villejuif, Paris Sud University Orsay, Paris France.
Thai AA; Medical Oncology Department, Peter MacCallum Cancer Institute, Melbourne, Australia.
Mascaux C; Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, CNRS, INSERM, CRCM, Marseille.
Couraud S; Respiratory Diseases and Thoracic Oncology Department, Lyon Sud Hospital, Cancer Institute of Hospices Civils de Lyon, Lyon 1 University.
Veillon R; CHU Bordeaux, Respiratory Diseases Department, Bordeaux, France.
Van den Heuvel M; Faculty of Medical Science, Radboud University Medical Center, Nijmegen, The Netherlands.
Neal J; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, USA.
Peled N; Soroka Medical Center, Ben-Gurion University, Beer-Sheva, Israel.
Früh M; Department of Oncology, Haematology, Cantonal Hospital St Gallen, St Gallen, University of Bern, Switzerland.
Ng TL; Thoracic Oncology Department, University of Colorado Cancer Center, Aurora, USA.
Gounant V; Department of Thoracic Oncology, CIC1425-CLIP2 Paris-Nord, Bichat-Claude Bernard Hospital, APHP, Paris, France.
Popat S; Royal Marsden Hospital, London, UK.
Diebold J; Cantonal Hospital, Lucerne, Switzerland.
Sabari J; Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA.
Zhu VW; Department of Medicine, Division of Hematology-Oncology, University of California, Irvine School of Medicine, Orange, USA.
Rothschild SI; Department Internal Medicine, University Hospital Basel, Medical Oncology, Basel, Switzerland.
Bironzo P; Department of Oncology, University of Torino, Torino, Italy.
Martinez-Marti A; Medical Oncology Department, Vall d'Hebron Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Curioni-Fontecedro A; Center of Hematology and Oncology, University Hospital Zurich, Switzerland.
Rosell R; Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
Lattuca-Truc M; Pulmonology Department, Grenoble University Hospital, Grenoble, France.
Wiesweg M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Besse B; Cancer Medicine Department, Gustave Roussy, Villejuif, Paris Sud University Orsay, Paris France.
Solomon B; Medical Oncology Department, Peter MacCallum Cancer Institute, Melbourne, Australia.
Barlesi F; Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, CNRS, INSERM, CRCM, Marseille.
Schouten RD; Faculty of Medical Science, Radboud University Medical Center, Nijmegen, The Netherlands.
Wakelee H; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, USA.
Camidge DR; Thoracic Oncology Department, University of Colorado Cancer Center, Aurora, USA.
Zalcman G; Department of Thoracic Oncology, CIC1425-CLIP2 Paris-Nord, Bichat-Claude Bernard Hospital, APHP, Paris, France.
Novello S; Department of Oncology, University of Torino, Torino, Italy.
Ou SI; Department of Medicine, Division of Hematology-Oncology, University of California, Irvine School of Medicine, Orange, USA.
Milia J; Thoracic Oncology Department, Toulouse University Hospital, Université Paul Sabatier, Toulouse, France.
Gautschi O; University of Bern and Cantonal Hospital, Lucerne, Switzerland.
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2019 Aug 01; Vol. 30 (8), pp. 1321-1328.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents, Immunological/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Biomarkers, Tumor/*genetics
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/mortality ; Female ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/immunology ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Mutation ; Oncogenes/genetics ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; Progression-Free Survival ; Registries/statistics & numerical data ; Response Evaluation Criteria in Solid Tumors ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
Autorzy :
Bonomi PD; Department of Internal Medicine, Rush University Medical Center, Chicago, USA. Electronic address: .
Gandara D; Department of Hematology and Oncology, UC Davis Comprehensive Cancer Center, Sacramento, USA.
Hirsch FR; University of Colorado Cancer Center, Aurora, USA.
Kerr KM; Department of Pathology, Aberdeen University Medical School and Aberdeen Royal Infirmary Foresterhill, Aberdeen, UK.
Obasaju C; Eli Lilly and Company, Indianapolis, USA.
Paz-Ares L; Hospital Universitario Doce de Octubre, Universidad Complutense, CiberOnc & CNIO, Madrid, Spain.
Bellomo C; Intermountain Cancer Center, Cedar City Hospital, Cedar City, USA.
Bradley JD; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, USA.
Bunn PA Jr; University of Colorado Cancer Center, Aurora, USA.
Culligan M; Division of Thoracic Surgery, University of Maryland School of Medicine, Baltimore, USA.
Jett JR; Emeritus, National Jewish Health, Denver, USA.
Kim ES; Levine Cancer Institute, Atrium Health, Charlotte, USA.
Langer CJ; Department of Thoracic Oncology, University of Pennsylvania Abramson Cancer Center, Philadelphia, USA.
Natale RB; Cedars-Sinai Comprehensive Cancer Center, West Hollywood, USA.
Novello S; Department of Oncology, University of Turin, Turin, Italy.
Pérol M; Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
Ramalingam SS; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, USA.
Reck M; Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany.
Reynolds CH; Florida Cancer Specialists, Ocala, USA.
Smit EF; Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, the Netherlands.
Socinski MA; Florida Hospital Cancer Institute, Orlando, USA.
Spigel DR; Sarah Cannon Research Institute, Nashville, USA.
Vansteenkiste JF; Respiratory Oncology Unit, Department of Respiratory Medicine, University Hospital KU Leuven, Leuven, Belgium.
Wakelee H; Stanford University School of Medicine, Stanford, USA.
Thatcher N; The Christie NHS Foundation Trust, Manchester, UK.
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2018 Aug 01; Vol. 29 (8), pp. 1701-1709.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Biomarkers, Tumor/*analysis
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Angiogenesis Inhibitors/pharmacology ; Angiogenesis Inhibitors/therapeutic use ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/genetics ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Gene Dosage ; Humans ; Lung/pathology ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Mutation ; Randomized Controlled Trials as Topic ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
Autorzy :
Wakelee H; Division of Oncology, Department of Medicine, Stanford University, Stanford, CA. Electronic address: .
Zvirbule Z; Medical Oncology Department, Riga Eastern Clinical University Hospital, Latvian Oncology Center, Riga, Latvia.
De Braud F; Medical Oncology Department, National Cancer Institute of Milan, Milan, Italy.
Kingsley CD; Clearview Cancer Institute, Huntsville, AL.
Mekhail T; Department of Hematology/Oncology, Florida Hospital, Orlando, FL.
Lowe T; Department of Medical Oncology, Cancer Care Associates Medical Group, Inc, Redondo Beach, CA.
Schütte W; Department of Internal Medicine II, Martha-Maria Krankenhaus Halle-Dölau gGmbH, Halle, Germany.
Lena H; Pneumology Service, Hôpital Pontchaillou, Rennes, France.
Lawler W; St Jude Heritage Medical Group, Fullerton, CA.
Braiteh F; Department of Medical Oncology, Comprehensive Cancer Centers of Nevada, Henderson, NV.
Cosgriff T; Division of Hematology/Oncology, Crescent City Research Consortium, Marrero, LA.
Kaen D; Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina.
Boyer M; Department of Clinical Science, F. Hoffmann-La Roche Ltd, Welwyn Garden City, UK.
Hsu J; Biostatistics Department, Product Development Oncology, Genentech Inc., San Francisco, CA.
Phan S; Biostatistics Department, Product Development Oncology, Genentech Inc., San Francisco, CA.
Novello S; Department of Oncology, AOU San Luigi-Orbassano, University of Turin, Turin, Italy.
Pokaż więcej
Źródło :
Clinical lung cancer [Clin Lung Cancer] 2017 Jan; Vol. 18 (1), pp. 50-59. Date of Electronic Publication: 2016 Oct 19.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Adenocarcinoma/pathology ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/administration & dosage ; Bevacizumab/administration & dosage ; Carboplatin/administration & dosage ; Carcinoma, Non-Small-Cell Lung/pathology ; Cisplatin/administration & dosage ; Double-Blind Method ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Paclitaxel/administration & dosage ; Pemetrexed/administration & dosage ; Prognosis ; Safety ; Survival Rate
Czasopismo naukowe
Tytuł :
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
Autorzy :
Crinò L; Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA. .
Ahn MJ; Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.
De Marinis F; Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.
Groen HJ; Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.
Wakelee H; Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.
Hida T; Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.
Mok T; Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.
Spigel D; Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.
Felip E; Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.
Nishio M; Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.
Scagliotti G; Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.
Branle F; Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.
Emeremni C; Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.
Quadrigli M; Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.
Zhang J; Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.
Shaw AT; Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2016 Aug 20; Vol. 34 (24), pp. 2866-73. Date of Electronic Publication: 2016 Jul 18.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Brain Neoplasms/*drug therapy
Brain Neoplasms/*secondary
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Pyrimidines/*therapeutic use
Receptor Protein-Tyrosine Kinases/*genetics
Sulfones/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Anaplastic Lymphoma Kinase ; Brain Neoplasms/enzymology ; Brain Neoplasms/genetics ; Carcinoma, Non-Small-Cell Lung/enzymology ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Crizotinib ; Female ; Gene Order ; Humans ; Lung Neoplasms/enzymology ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Organoplatinum Compounds/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use ; Pyrazoles/administration & dosage ; Pyridines/administration & dosage ; Pyrimidines/adverse effects ; Receptor Protein-Tyrosine Kinases/antagonists & inhibitors ; Sulfones/adverse effects
Czasopismo naukowe
Tytuł :
Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor--Mutated Non--Small-Cell Lung Cancer With T790M Mutations.
Autorzy :
Castellanos EH; Vanderbilt University Medical Center, Nashville, TN. Electronic address: .
Rivera G; Stanford University Medical Center, Stanford, CA.
Wakelee H; Stanford University Medical Center, Stanford, CA.
Horn L; Vanderbilt University Medical Center, Nashville, TN.
Pokaż więcej
Źródło :
Clinical lung cancer [Clin Lung Cancer] 2015 Sep; Vol. 16 (5), pp. e97-9. Date of Electronic Publication: 2015 Mar 05.
Typ publikacji :
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
ErbB Receptors/*genetics
Lung Neoplasms/*drug therapy
Afatinib ; Aged ; Antibodies, Monoclonal/administration & dosage ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Drug Resistance, Neoplasm ; Female ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Middle Aged ; Mutation ; Panitumumab ; Quinazolines/administration & dosage
Czasopismo naukowe
Tytuł :
A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.
Autorzy :
Chen H; Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA.
Modiano MR; Arizona Oncology/Arizona Clinical Research Center, 1620W. St Mary's Rd, Tucson, AZ 85745, USA.
Neal JW; Department of Medicine, Stanford University School of Medicine and Cancer Institute, 875 Blake Wilbur Dr, Stanford, CA 94305, USA.
Brahmer JR; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting/Blaustein CRB, 1650 Orleans St., G94, Baltimore, MD 21231, USA.
Rigas JR; Department of Medicine, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, 1 Medical Center Drive, Lebanon, NH 03756, USA.
Jotte RM; Rocky Mountain Cancer Centers, 1800 Williams Street, Suite 200, Denver, CO 80218, USA.
Leighl NB; Department of Medicine, Princess Margaret Hospital and University of Toronto, 610 University Avenue, Toronto, ON M5G 2M9, Canada.
Riess JW; Department of Medicine, Stanford University School of Medicine and Cancer Institute, 875 Blake Wilbur Dr, Stanford, CA 94305, USA.
Kuo CJ; Department of Medicine, Stanford University School of Medicine and Cancer Institute, 875 Blake Wilbur Dr, Stanford, CA 94305, USA.
Liu L; Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA.
Gao B; Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA.
Dicioccio AT; Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA.
Adjei AA; Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA.
Wakelee HA; Department of Medicine, Stanford University School of Medicine and Cancer Institute, 875 Blake Wilbur Dr, Stanford, CA 94305, USA.
Pokaż więcej
Źródło :
British journal of cancer [Br J Cancer] 2014 Feb 04; Vol. 110 (3), pp. 602-8. Date of Electronic Publication: 2013 Nov 28.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Carcinoma, Non-Small-Cell Lung/*drug therapy
Cisplatin/*administration & dosage
Glutamates/*administration & dosage
Guanine/*analogs & derivatives
Receptors, Vascular Endothelial Growth Factor/*administration & dosage
Recombinant Fusion Proteins/*administration & dosage
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Cisplatin/adverse effects ; Disease-Free Survival ; Drug-Related Side Effects and Adverse Reactions/classification ; Drug-Related Side Effects and Adverse Reactions/pathology ; Female ; Glutamates/adverse effects ; Guanine/administration & dosage ; Guanine/adverse effects ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Pemetrexed ; Receptors, Vascular Endothelial Growth Factor/adverse effects ; Recombinant Fusion Proteins/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours.
Autorzy :
Diaz-Padilla I; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Hospital, University Health Network, University of Toronto, 610 University Avenue, 5-700, Toronto, Ontario M5G 2M9, Canada. />Siu LL
San Pedro-Salcedo M
Razak AR
Colevas AD
Shepherd FA
Leighl NB
Neal JW
Thibault A
Liu L
Lisano J
Gao B
Lawson EB
Wakelee HA
Pokaż więcej
Źródło :
British journal of cancer [Br J Cancer] 2012 Aug 07; Vol. 107 (4), pp. 604-11. Date of Electronic Publication: 2012 Jul 17.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cisplatin/*administration & dosage
Glutamates/*administration & dosage
Guanine/*analogs & derivatives
Neoplasms/*drug therapy
Recombinant Fusion Proteins/*administration & dosage
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Drug Administration Schedule ; Fatigue/chemically induced ; Female ; Guanine/administration & dosage ; Humans ; Male ; Maximum Tolerated Dose ; Middle Aged ; Nausea/chemically induced ; Pemetrexed ; Receptors, Vascular Endothelial Growth Factor ; Recombinant Fusion Proteins/blood
Czasopismo naukowe
Tytuł :
Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell lung cancer.
Autorzy :
Das M; Department of Medicine, Division of Oncology, Stanford University, CA, USA.
Donington JS
Murphy J
Kozak M
Eclov N
Whyte RI
Hoang CD
Zhou L
Le QT
Loo BW
Wakelee H
Pokaż więcej
Źródło :
Clinical lung cancer [Clin Lung Cancer] 2011 Sep; Vol. 12 (5), pp. 280-5. Date of Electronic Publication: 2011 Jul 14.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*therapy
Lung Neoplasms/*therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Area Under Curve ; Carboplatin/administration & dosage ; Carcinoma, Non-Small-Cell Lung/pathology ; Combined Modality Therapy ; Disease-Free Survival ; Docetaxel ; Female ; Humans ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Prospective Studies ; Survival Rate ; Taxoids/administration & dosage ; Treatment Outcome ; Tumor Burden
Czasopismo naukowe
Tytuł :
Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial.
Autorzy :
West HL; Thoracic Oncology Program, Department of Medical Oncology, Swedish Cancer Institute, Seattle, WA 98104, USA. />Wakelee HA
Perry MC
Belt RJ
Chen R
Obasaju C
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2009 May; Vol. 20 (5), pp. 850-6. Date of Electronic Publication: 2009 Jan 15.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Disease-Free Survival ; Drug Administration Schedule ; Female ; Folic Acid Antagonists/administration & dosage ; Glutamates/administration & dosage ; Guanine/administration & dosage ; Guanine/analogs & derivatives ; Humans ; Kaplan-Meier Estimate ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Pemetrexed ; Time Factors ; Treatment Outcome ; United States/epidemiology
Czasopismo naukowe
Tytuł :
Second- and third-line treatments in non-small cell lung cancer.
Autorzy :
Kumar A; Stanford Cancer Center, Stanford, CA 94305, USA. />Wakelee H
Pokaż więcej
Źródło :
Current treatment options in oncology [Curr Treat Options Oncol] 2006 Jan; Vol. 7 (1), pp. 37-49.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Clinical Trials as Topic ; Drug Approval ; Humans ; Prognosis ; Quality of Life ; Salvage Therapy ; United States ; United States Food and Drug Administration
Czasopismo naukowe
Tytuł :
A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer.
Autorzy :
Wakelee H; Stanford Clinical Cancer Center, Stanford, CA 94305-5826, USA. />Fisher GA
Pokaż więcej
Źródło :
Investigational new drugs [Invest New Drugs] 2005 Jun; Vol. 23 (3), pp. 241-2.
Typ publikacji :
Clinical Trial; Clinical Trial, Phase I; Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Colorectal Neoplasms/*drug therapy
Colorectal Neoplasms/*pathology
Adult ; Amifostine/administration & dosage ; Camptothecin/administration & dosage ; Camptothecin/adverse effects ; Camptothecin/analogs & derivatives ; Cytoprotection ; Dose-Response Relationship, Drug ; Humans ; Irinotecan ; Neoplasm Metastasis
Czasopismo naukowe
    Wyświetlanie 1-13 z 13

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies